Skip to content
  • Friday, 14 August 2026
  • 10:18 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Laboratory Automation & Robotics

Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s

Lana Keisha Jul 25, 2026 0

A new paradigm in therapeutic development is emerging as Remepy, a pioneering startup, successfully completed a Phase IIa clinical trial…

Read More
Laboratory Automation & Robotics

Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s

Lana Keisha Jul 10, 2026 0

A new era in therapeutic innovation is dawning, marked by the successful Phase IIa clinical trial results for Hybridopa, an…

Read More
Laboratory Automation & Robotics

Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s

Lana Keisha Jun 29, 2026 0

In a significant advancement for integrated medicine, Remepy, a pioneering startup, has announced successful Phase IIa clinical trial results for…

Read More
Laboratory Automation & Robotics

Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s.

Lana Keisha Jun 22, 2026 0

A significant stride in the realm of integrated medicine has been reported by Remepy, a pioneering startup, as its innovative…

Read More
Laboratory Automation & Robotics

Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s

Lana Keisha Jun 15, 2026 0

In a significant advancement for integrated medicine, Remepy, a pioneering startup, has announced successful Phase IIa clinical trial results for…

Read More
Amphibian Recovery Mystery Solved: Early Immune Development Crucial for Survival Against Deadly FungusDemystifying the .claude Folder: A Deep Dive into AI Tool Local State ManagementIntroducing the distinguished judging panel for the BioTechniques 2026 Image Competition.Groundbreaking Nanodisc Platform Unveils Unprecedented Insights into Viral Protein-Antibody Interactions, Promising Accelerated Vaccine Development
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactLLMOps in 2026: The 10 Tools Every Team Must HaveThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ